Training program

We offer a program in the use of 3D structural modeling to assess the clinical impact of drugs based on the patient’s genetic fingerprint




1 day


The course is designed to explain how mutations will impact the behaviour of a cancer driving protein (the target) and its susceptibility to drugs. Our target audience is clinicians who wish to know how to use modeling approaches to select from available drugs. Attendees will be shown how to visualize the patient’s protein structure and taught how to evaluate the interactions made between the drug and the target. Using publicly available databases and freeware visualisation software, the attendees will also be shown how to create models of mutated targets and to assess the impact of these mutations on the interaction between the drug and its target. Examples of software solutions to model these changes, ranging from the simplistic to the complex will also be discussed.

Why attend this course

This course will provide you with an understanding of how the drivers of disease look on a molecular level and how changes to these drivers impact the selection of treatment. The potential to explain how drug efficacy may be impacted by gene mutation is also of potential benefit in explaining treatment choices to patients.

What items will be discussed

  • Successful use cases of molecular modeling to guide treatment choice
    Publicly available (freeware) software and databases for drug:target visualization
  • How drug interact with their target on a molecular scale
  • How to create models of patient mutations
  • How to analyse the impact of mutations on protein behaviour and drug interaction

Prof. dr. Matthew Groves
CSO Protyon

University of Groningen.
Faculty of Science and Engineering.